Regulus Therapeutics (NASDAQ:RGLS): FDA Clears Trial: Stock Soars 55%

May 12, 2022

Regulus Therapeutics (NASDAQ:RGLS) soared 55% after the clinical-stage biotech firm disclosed that the FDA had accepted its RGLS8429 Investigational New Drug Application in hereditary kidney disorders. The IND application was submitted in order to obtain regulatory approval to examine RGLS8429 in hereditary autosomal dominant polycystic kidney disease (ADPKD). ADPKD is a genetically based disease that is a leading cause of end-stage renal failure. Trading Data On Wednesday, RGLS stock soared…

Read More >>